By selling its China business to AstraZeneca, FibroGen can focus on developing a prostate cancer drug and potentially ...

The news comes on the heels of promising Phase I/Ib data, which point to the potential of casdatifan as a more effective ...

Arcus Biosciences Inc. (NYSE: RCUS) shares are trading lower Tuesday after the company announced a $150 million common stock ...

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination ...

Gilead Sciences has defied analysts’ expectations by passing on its chance to license Arcus Biosciences’ potential rival to Merck & Co.’s kidney cancer drug Welireg.

Arcus Biosciences (RCUS) presented new data for casdatifan, a HIF-2a inhibitor with best-in-class potential, in an oral plenary session by Dr.

Bhubaneswar: Chile-based e-fuel company HIF Global has expressed interest to invest around $1 billion in Odisha’s renewable ...

Casdatifan’s progression-free survival benefits could help differentiate it from Merck’s Welireg in the kidney cancer arena, ...

Casdatifan targets a transcription factor that binds with other proteins to switch off the body’s anti-inflammatory ...

The Uruguayan Ministry of Environment has in hand a project to build a photovoltaic power station with more than 1,844,400 ...

Casdatifan showed improvement in primary progressive disease rate (progressed at or before their first disease assessment), ORR and mPFS relative to published data from studies with HIF-2a ...

Chile-based HIF Global is set to invest USD 1 billion in Odisha's renewable energy sector, focusing on a methanol synthesis ...